The Discounted Cash Flow (DCF) valuation of Cyclacel Pharmaceuticals Inc (CYCC) is (83,323,657.72) USD. With the latest stock price at 1.62 USD, the upside of Cyclacel Pharmaceuticals Inc based on DCF is -5143435761.4%.
Based on the latest price of 1.62 USD and our DCF valuation, Cyclacel Pharmaceuticals Inc (CYCC) is a sell. selling CYCC stocks now will result in a potential gain of 5143435761.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.6% - 8.1% | 7.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (175,342,967.64) - (54,835,770.27) | (83,323,657.72) |
| Upside | -10823640077.7% - -3384924190.9% | -5143435761.4% |